Alcohol consumption is ubiquitous across the globe, particularly among developed countries. There is convincing evidence that alcohol increases risk for breast cancer with a dose-response starting at low intake levels ([@bib52]; [@bib41]; [@bib23]). Alcohol may affect breast cancer risk through several potential mechanisms including acetaldehyde promotion of tumour initiation, ethanol metabolism-induced oxidative stress and tumour promotion, altered metabolism and clearance of carcinogens, and impaired immunity, as well as increased circulating sex steroid hormones, in part through aromatisation of androgens to oestrogens ([@bib20]; [@bib26]).

Evidence from large, pooled analyses of prospective studies ([@bib26]) and several randomised-controlled crossover feeding studies ([@bib9]; [@bib31]; [@bib44]) that used 95% ethanol as the alcohol exposure has shown that alcohol consumption is associated with higher circulating parent oestrogens (oestradiol, oestrone), androstenedione, dehydroepiandrosterone sulphate (DHEAS), testosterone, and lower sex hormone binding globulin (SHBG). Parent oestrogens can be irreversibly hydroxylated at steroid ring carbon positions 2, 4, or 16 to yield 2-, 4- or 16-hydroxylated oestrogen metabolites ([@bib22]). These pathways are interrelated, with metabolite concentrations within each pathway dependent on the overall oestrogen substrate pool. The mitogenic and genotoxic properties of oestrogen metabolites that affect cancer risk have been shown to differ by oestrogen metabolic pathway, partly influenced by degree of hydroxylation and/or methylation ([@bib4]; [@bib54]; [@bib5]; [@bib8]; [@bib39]). For example, in prospective studies utilising liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure oestrogen/oestrogen metabolites, relative increase in levels of 2-hydroxylation pathway metabolites to total has been associated with reduced breast cancer risk ([@bib39]). Oestrogen metabolism is consequently a highly complex hormonal exposure characterised by competing metabolic pathways. To understand the potential effects of alcohol on the hormonal mechanisms that drive cancer risk, a better understanding of downstream metabolic influences is needed.

Studies that explore the relationship between alcohol intake and oestrogen metabolism that include oestrogen pathway metabolites are limited ([@bib18]), and none, to our knowledge, have been conducted among postmenopausal women. Our objective was to examine associations of circulating serum oestrogen/oestrogen metabolite concentrations (in conjugated and unconjugated forms) with alcohol consumption, stratified by menopausal hormone therapy (MHT) use, in postmenopausal women participating in a nested case-control study within the Women's Health Initiative (WHI) Observational Study (OS). We hypothesised that alcohol drinkers would have higher parent oestrogens and oestrogen metabolites, and lower 2-pathway metabolites, favouring a pro-oestrogenic effect of alcohol with metabolism of parent oestrogen into 4- and 16-pathway compared with the 2-pathway metabolites.

Materials and methods
=====================

Study population
----------------

The WHI-OS is a prospective cohort that enrolled 93 676 postmenopausal women aged 50--79 years at 40 clinical centres across the United States between 1993 and 1998 ([@bib48]). We conducted a cross-sectional analysis of baseline data from a nested ovarian and endometrial cancer case-control study within the WHI-OS (*N*=1864 women, *N*=510 cases and 473 controls among never/former MHT users; *N*=458 cases and 423 controls among current MHT users) ([@bib49]; [@bib3]). Both dietary information and blood samples were prospectively collected prior to cancer development. Cases and controls were enrolled into the prospective observational study based on the same selection criteria; thus cases and controls were pooled for cross-sectional analysis. These data were obtained an average of 6.9±3.7 years prior to endometrial cancer diagnosis and 6.9±3.8 years prior to ovarian cancer diagnosis among the cases. Cases were women diagnosed with incident invasive ovarian or endometrial cancer between study enrolment and May 2012, and controls were frequency matched to cases on age at venepuncture (50--54, 55--59, 60--64, 65--69, 70--74, 75--79 years), year at venepuncture (1993--1996, 1997--1998), race/ethnicity (white, black, Hispanic, other/unknown), and time since last MHT use (⩽1, \>1 year). Controls were alive and cancer-free at the date of diagnosis of their matched case. Eligible women had no history of cancer, besides non-melanoma skin cancer, no history of bilateral oophorectomy or hysterectomy (endometrial controls only), and had adequate prediagnosis serum sample volume available (1.1 ml). Demographic, medical and family history, and lifestyle information was collected via a baseline questionnaire. The study was approved by the institutional review board at the Fred Hutchinson Cancer Research Centre (WHI Clinical Coordinating Centre) and all participating clinical centres. All participants provided written informed consent to participate.

Exposure assessment
-------------------

Alcohol intake was measured by 122-item self-administered food frequency questionnaire (FFQ) at the same clinic visit as the fasting venepuncture. The FFQ was previously calibrated against both 24-h dietary recalls and 4-day food records ([@bib35]). The FFQ asked questions about frequency of intake (never/\<1 per month to ⩾6 servings per day) of specific portion sizes of alcohol (12 oz or 1 can beer, 6 oz or 1 medium glass wine, and 1.5 oz or 1 shot liquor). A personal habits questionnaire also inquired about ever alcohol use (12 alcoholic beverages ever- no, yes, missing), and current alcohol use (no, yes, missing). Total alcohol intake (beer, wine and liquor) was calculated, converted into number of standard drinks/week and categorised (non-drinker *versus* current drinker; drinking categories: \<1, 1--\<3, 3--\<7, ⩾7 drinks/week). One serving of beer, wine, or liquor per week contained the same amount of alcohol (approximately 15 g, on average). Alcohol type was also categorised to reflect overall consumption patterns: (1) non-drinker, drinker but not liquor, \>0--1, \>1 drink/week for liquor; (2) non-drinker, drinker but not beer, \>0--1, \>1 drink/week for beer; and (3) non-drinker, drinker but not wine, \>0--1, \>1--3, \>3 drinks/week for wine).

Laboratory assay
----------------

Fifteen fasting serum oestrogens and oestrogen metabolites were quantified using stable isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) (Leidos Biomedical Research, Inc., Frederick, MD, USA) (25). Quantified metabolites included: unconjugated and combined (unconjugated+conjugated) oestrone and oestradiol (parent oestrogens), and 13 oestrogen metabolites (2-hydroxyoestrone, 2-hydroxyoestradiol, 2-hydroxyoestrone-3-methyl ether, 4-hydroxyoestrone, 4-methoxyoestrone, 4-methoxyoestradiol, 16*α*-hydroxyoestrone, 16-ketoestradiol, 16-epioestriol, 17-epioestriol, as well as unconjugated and combined oestriol, 2-methoxyoestrone, and 2-methoxyoestradiol). Conjugated concentrations of oestrone, oestradiol, oestriol, 2-methoxyoestrone, and 2-methoxyoestradiol were calculated by subtracting unconjugated from total combined concentration. Assay reliability was assessed using masked technical replicates analysed across batches. Coefficients of variation (CV) were \<6% for all analytes; median (range) intraclass correlation coefficients (ICC) across all analytes was 0.98 (0.93--0.996) ([@bib49]; [@bib3]).

Statistical analysis
--------------------

### Primary analysis

Since the serum samples for the nested case-control study of ovarian and endometrial cancer were collected prior to diagnosis, we included both cases and controls (*N*=1864) in this cross-sectional analysis. Geometric means (GM, pmol l^−1^) of oestrogen/oestrogen metabolite concentrations were calculated by (1) overall alcohol exposure category and (2) alcohol type category (liquor, beer, wine) using inverse probability weighted linear regression. Analyses were re-weighted by inverse probability sampling weights to account for case-control selection criteria and to represent the WHI-OS cohort ([@bib29]). Sampling weights were the inverse of sampling fractions for cases (one) and controls (adjusted depending on strata and matching factors). Serum concentrations of oestrogen/oestrogen metabolites were evaluated individually, and in unconjugated and combined forms for select analytes. Analytes were log-transformed to account for non-normality. All analyses were multivariable and adjusted for *a priori*-defined potential confounders ([@bib25]; [@bib42]; [@bib6]; [@bib27]; [@bib11]; [@bib2]; [@bib45]): venepuncture age (\<60, 60--\<70, ⩾70 years), venepuncture year (1993--1996, 1997--1998), race (white, non-white), smoking status (never, past, current), body mass index (BMI) (kg m^−2^, continuous), years since menopause (\<10 years, 10--\<20 years, ⩾20), oral contraceptive use duration (0, \<5, ⩾5 years), caffeine intake (quartiles), sedentary/sitting time (\<5, 5--\<10, ⩾10 h per day), and metabolic equivalent (MET) hours of physical activity/week (none, \>0--\<7.5, 7.5--15 (National recommendations), ⩾15). We conducted Wald tests for trend among alcohol drinkers using the median values of the alcohol categories (servings/week). We ran restricted cubic spline regression on alcohol associations with unconjugated and conjugated parent oestrogens, creating 5-knot splines at the 5th, 25th, 50th, 75th, and 95th percentiles of number of alcohol servings/week ([@bib10]). The main analyses were stratified by never/former MHT users *versus* current users given that oestrogen/oestrogen metabolite concentrations vary by MHT use.

### Sensitivity analyses

*Stratification and Effect Modification:* In sensitivity analyses, we excluded: (1) cancer cases, (2) women with diabetes, (3) oestrogen metabolite outliers, (4) alcohol intake outliers. We tested for effect modification with the inclusion of an alcohol-modifier interaction term in the main analyses. Outliers were identified using an extreme studentised deviate many-outlier procedure ([@bib38]).

*Confounding*: We evaluated the role of MHT formulation (unopposed oestrogen use, both oestrogen and progesterone use, or a combination of one of these formulations with past use of the other formulation) by further adjusting analyses of total alcohol intake and oestrogen/oestrogen metabolite concentrations for MHT formulation among current MHT users. MHT dosage did not vary substantially among MHT users. We also further adjusted select metabolite findings for parent oestrogens to assess whether their associations with alcohol were independent. We additionally controlled alcohol type for total alcohol consumption. We also checked for residual confounding by smoking by adjusting for cigarette pack years.

*Metabolite ratio:* Finally, we evaluated associations between overall alcohol intake and oestrogen/oestrogen metabolite ratios, including: ratio of parent to total oestrogens; ratio of unconjugated to combined oestrone, oestradiol, oestriol, 2-methoxyoestrone, and 2-methoxyoestradiol; ratio of 2-hydroxyoestrone to 4-hydroxyoestrone; ratio of 2-hydroxyoestrone to 16-alpha-hydroxyoestrone, and ratio of 4-hydroxyoestrone to 16-alpha-hydroxyoestrone. We calculated *P*-value for trends of increasing/decreasing metabolite ratios across alcohol drinking categories.

All *P*-values were two-sided and considered statistically significant if less than 0.05. For descriptive purposes, we also calculated the false discovery rate (FDR), and set a threshold of less than 0.05 as a second, more stringent, threshold of statistical significance (Benjamini--Hochberg procedure) ([@bib1]; [@bib12]). All analyses were conducted with appropriate sampling weights using SAS Survey Procedures (PROC SURVEYREG, SAS version 9.3, SAS Institute, Cary, NC, USA).

Results
=======

Study population
----------------

In this cross-sectional analysis among 1864 women participating in the WHI-OS, never/former MHT users were aged 64±7 years and current MHT users were aged 63±7 years at their baseline visit, on average ([Table 1](#tbl1){ref-type="table"}). Most women were Caucasian, non-smokers that met national physical activity guidelines (⩾7.5 MET hours per week), had an average BMI in the overweight range (25--\<30 kg m^−2^), and had been in menopause for \>10 years. Thirty-nine percent of never/former MHT users and 55% of current MHT users had a history of oral contraceptive use.

Alcohol intake
--------------

The median (interdecile range) servings/week of alcohol was 0.4 (0, 8.3) among never/former MHT users and 0.7 (0, 8.7) among current MHT users. Among drinkers, median (interdecile range) servings/week alcohol was 2.6 (0.2, 16.0) among never/former MHT users and 2.7 (0.4, 10.9) among current MHT users. Twenty-nine percent of never/former MHT users reported not currently being alcohol drinkers (*N*=280), compared with 22% of current MHT users (*N*=190). Median (interdecile range) standard drinks/week of alcohol types were: (1) beer 0.42 (0.21, 7.00), liquor 1.00 (0.21, 7.88), wine 1.00 (0.21, 7.00) among never/former MHT users; (2) beer 0.42 (0.21, 2.72), liquor 0.49 (0.21, 7.00), wine 1.36 (0.21, 7.88) among current MHT users.

Among never/former MHT users, the highest category of drinkers had higher circulating oestrogens and 2-, 4-, and 16-pathway metabolite concentrations compared with no current alcohol intake, although associations were not statistically significant ([Table 2](#tbl2){ref-type="table"}). Among MHT users who were drinkers, increasing alcohol intake (GM for 7+ compared with \<1 drink per week) was associated with higher concentrations of unconjugated oestrone (26% increase, *p*-trend=0.01), unconjugated and conjugated oestradiol (26 and 29% increases, respectively, *p*-trend=0.04), unconjugated 2-methoxyoestrone (37% increase, *p*-trend=0.01), and unconjugated 2-methoxyoestradiol (17% increase, *p*-trend=0.04) ([Table 3](#tbl3){ref-type="table"}). However, these trends did not meet FDR\<0.05. The trends for increasing unconjugated oestrone (*P*=0.02) and oestradiol (*P*=0.03) with increasing servings of alcohol/week among MHT users were linear based on cubic spline regression analysis (results not shown). Results were not materially changed with finer adjustment for cigarette pack years (analyte concentrations changed 1--12%), although nominal statistical significance was retained only for increasing trends of unconjugated oestrone, 2-methoxyestrone, and 2-methoxyestradiol among current MHT users.

Among never/former MHT users, liquor consumption was associated with 19--32% increases in GM of parent oestrogen and oestrogen metabolite concentration for highest level compared with no intake of that alcohol type (*p*-trend across current liquor drinkers=0.001 to 0.04), including: combined and conjugated oestrone, unconjugated oestradiol, 2-hydroxyoestrone, and 2-hydroxyoestradiol, combined and conjugated 2-methoxyoestrone, unconjugated 2-methoxyoestradiol, 3-methyl ether-hydroxyoestrone, 4-hydroxyoestrone, 4-methoxyoestrone, 16-alpha-hydroxyoestrone, all three measures of oestriol, 16-ketoestradiol, 16-epioestriol, and 17-epioestriol. FDR was \<0.05 for all associations ([Table 4](#tbl4){ref-type="table"}; see [Supplementary Table 1](#sup1){ref-type="supplementary-material"} for current MHT users). These associations were not retained after further adjustment for parent oestrogens. Consumption of beer and wine were not associated with oestrogen/oestrogen metabolites. Findings were not materially altered with further adjustment for total alcohol intake (data not shown).

Since we observed alcohol associations primarily with the unconjugated component of oestrogen/oestrogen metabolites, we compared the proportion of unconjugated to combined concentration for these hormones across drinking categories ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Trends for decreasing ratio of unconjugated to combined oestrone (18% *versus* 20% for 7+ compared with \<1 drink per week) and 2-methoxyoestradiol (16% *versus* 18% for 7+ compared with \<1 drink per week) were evident among never/former MHT users, while a trend for increasing unconjugated to combined 2-methoxyoestrone (40 *vs* 33% for 7+ compared with \<1 drink per week) was evident for increasing categories of alcohol intake among current MHT users. For liquor, highest category compared with no liquor consumption was inversely associated with ratio of unconjugated to combined oestrone (17 *vs* 21% for \>1 compared with no liquor intake). These trends did not meet FDR\<0.05.

We further excluded cases (*N*=510 never/former MHT users; *N*=458 current MHT users; [Supplementary Table 3](#sup1){ref-type="supplementary-material"}) and women with diabetes (*N*=42 never/former MHT users; *N*=28 current MHT users; results not shown) from the overall alcohol and liquor analyses. There were no differences in the association between overall alcohol consumption and oestrogen/oestrogen metabolites between cases and controls, or between women with and without diabetes. There was no evidence for alcohol-case status effect modification (all *P*-values for interaction\>0.05). Similarly, excluding cases and women with diabetes did not alter the patterns of association for liquor consumption. When we removed oestrogen metabolite outliers or alcohol outliers (results not shown), unconjugated oestrone and 2-methoxyoestrone remained nominally associated with overall alcohol consumption among MHT users. When we additionally adjusted for MHT formulation ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}), we observed similar trends among MHT users for the main effects of alcohol consumption on oestrogen and 2-hydroxylation pathway catechol oestrogen metabolites.

Discussion
==========

In this population of 1864 postmenopausal women from a nested case-control study within the WHI-OS cohort, we observed nominal associations for increasing concentrations of parent oestrogens with increasing alcohol intake among both never/former and current MHT users, consistent with prior studies. We also observed trends of increased 2-hydroxylation pathway oestrogen metabolites with increasing alcohol intake, although trends did not meet the FDR threshold. Liquor was associated with increased concentrations of circulating parent oestrogens and 2-, 4-, and 16-pathway oestrogen metabolites among never/former MHT users across frequency of use categories; oestrogen metabolite associations with liquor intake did not remain with further adjustment for parent oestrogens.

Prior randomised dietary interventions and prospective studies have supported that alcohol intake is associated with postmenopausal hormone levels. The Women's Alcohol study, a placebo controlled 8-week crossover feeding study among 51 healthy postmenopausal women not using MHT, showed that 15--30 g per day alcohol intake increased serum oestrone sulphate by 7.5--10.7% and DHEAS by 5.1--7.5% ([@bib9]). In a pooled meta-analysis of 13 prospective studies (*N*=6291) from across the globe, sex hormone concentrations were ∼10--25% higher among postmenopausal women consuming ⩾20 g alcohol per day (∼20% women) compared with non-drinkers, including oestradiol, oestrone, androstenedione, DHEAS, and testosterone; SHBG concentrations were reduced by 10% ([@bib26]). Fifteen to 30 g alcohol per day approximates one to two standard drinks/day, in contrast to median intakes of ∼0.4 standard drinks/day among drinkers in our population. The effect sizes we observed in our analysis for parent oestrogens were consistent with these prior studies, but did not reach statistical significance, possibly due to sample size.

Few prior studies have evaluated associations of alcohol consumption with circulating sex steroid hormone metabolites, which may provide insight into alcohol's potential role in modifying oestrogen metabolic pathways. Understanding how alcohol influences endogenous metabolic pathways is of high importance given that the biological mechanisms underlying alcohol's strong association with breast and other cancers, which include sex steroid hormone metabolism, remain poorly defined. Alcohol may influence oestrogen metabolism through increased aromatase activity in the liver and other tissues, stimulating conversion of androgens to oestrogens ([@bib36]), decreased catabolism of sex hormones by the liver through accumulation of hepatic nicotinamide-adenine dinucleotide (NADH) -- leading to oxidation and inhibition of oestradiol conversion to oestrone ([@bib15]), and direct/indirect adrenal gland cell signalling promotion for DHEAS production (a precursor of oestradiol) ([@bib34]; [@bib43]). How alcohol associates with different oestrogen hydroxylation pathways among postmenopausal women, however, is unknown. A recent analysis evaluated associations of alcohol intake with parent oestrogen/oestrogen metabolites, although women were pre-menopausal and metabolites were measured in urine ([@bib18]). Alcohol intake was only associated with oestradiol, but not other parent oestrogens/metabolites. Although menopausal status has not been shown to be a significant modifier of the alcohol-breast cancer association ([@bib51]), the majority of breast cancer cases are diagnosed after menopause, with elevated circulating oestrogens being a strong risk factor ([@bib24]), highlighting the importance of evaluating alcohol's effects on oestrogen metabolism in this population.

Evaluating ratios of unconjugated to combined oestrogens provides insight into how the pattern of metabolism might vary between never/former and current MHT users. We saw that circulating oestrogen metabolites among MHT users were predominantly conjugated in comparison with non-users. Relative concentration of parent to total oestrogens was also higher, suggesting a potential mechanism for enhanced breast cancer risk with alcohol intake in MHT users. Similar to our observation of an overall alcohol association with parent oestrogens among MHT users, moderate alcohol consumption increased circulating oestradiol among postmenopausal women using MHT but not those who were not on MHT in a randomised, double-blind, placebo-controlled, crossover feeding study ([@bib15]). Furthermore, among postmenopausal women in a prospective cohort (*N*=5035), an interaction between intake of two or more alcoholic drinks per day and MHT use was observed for risk of developing breast cancer; drinkers that also used MHT had an increased risk of breast cancer compared with non-MHT users that abstained from alcohol (HR=1.27, 95% CI=1.09--1.49 per 1 drink/day increase, *p*-trend=0.004 among MHT users; HR=0.98, 95% CI=0.82--1.78 per 1 drink/day increase, *p*-trend=0.79 among non MHT users) ([@bib33]). An alcohol-MHT synergistic effect on breast cancer has been supported by analyses within four other large, prospective cohorts ([@bib13]; [@bib7]; [@bib47]; [@bib55]). A biological rationale for these findings has been suggested, including decreased conversion of oestrogen to its metabolites, a shift in metabolism to different hydroxylation pathways ([@bib15]), and altered rate of ethinyloestradiol clearance ([@bib16]) among MHT users. In our analysis, drinkers who were taking MHT consumed more total alcohol, on average, than never/former MHT users. It is also possible that dose of alcohol consumption among women in our study may have influenced the differences in magnitudes of association we observed between MHT groups.

We found that highest compared with lowest category of liquor intake among drinkers was associated with 20--30% increases in both parent oestrogens and 2-, 4-, and 16-hydroxylation pathway metabolites among never/former MHT users. In contrast to total alcohol consumption, never/former MHT users consumed more liquor, on average, than current MHT users. The liquor associations remained with further adjustment for total alcohol intake. When we additionally adjusted for parent oestrogens, the pathway associations were not retained, suggesting that they were not independent of parent oestrogens. This might suggest increased oestrogen formation/reduced catabolism as opposed to hydroxylation pathway effects. The ratio of unconjugated to combined oestrone was nominally reduced with higher liquor consumption, which suggests increased oestrone sulphation or glucuronidation (conversion to oestrone sulphate/glucuronide). Sulphated oestrone is stored as an oestrogen substrate reservoir, whereas glucuronidated oestrone is excreted ([@bib19]). Few studies have evaluated associations of sex hormones by types of alcohol, in part due to limitations in sample size ([@bib30]; [@bib17]; [@bib32]; [@bib18]). Feeding studies have generally utilised 95% ethanol as the alcohol exposure thus have not evaluated wine or beer intake ([@bib9]; [@bib31]). Further research on differences in sex steroid hormone metabolism by alcohol type is warranted. Polyphenols in red wine have been shown to be a cancer chemopreventive agent ([@bib40]). Nonetheless, updated dose-response meta-analyses support that all alcohol types, including red wine intake, are associated with increased risk for colorectal and breast cancers ([@bib52]; [@bib53]). While we did not observe an association of wine or beer intake with oestrogen metabolism, it is possible that these alcohol types increase cancer risk through other mechanisms such as formation of acetaldehyde, oxidative stress, altered carcinogen clearance, and impaired immunity.

In the context of cancer prevention, understanding hormonal mechanisms influenced by lifestyle exposures like alcohol consumption may provide targets for cancer prevention intervention in high risk populations. In the same population of women to the current study, parent oestrogens were found to be positively related to endometrial cancer risk (particularly unconjugated oestradiol) ([@bib3]). Higher oestrone, and 2- and 4- and 16-pathway metabolites were also associated with non-serous ovarian cancer risk ([@bib50]). Our data from the current analysis support current recommendations to limit alcohol consumption for cancer prevention.

Strengths of our study include the high reliability, sensitivity and specificity of the LC-MS/MS assay, comprehensive evaluation of oestrogen/oestrogen metabolites by exogenous hormone use, and the ability to evaluate associations by alcohol type. However, several limitations exist. The median dose of alcohol consumption in our study was modest and may have been inadequate to enable us to detect associations with oestrogen metabolism. Additionally, sample size may have been limited to detect statistically significant associations, given adjustment for multiple comparisons. We were unable to evaluate earlier life alcohol exposure, which may have been higher than postmenopausal consumption. Additionally, the current analysis was cross-sectional at the time of entry into the study. We did not evaluate how alcohol intake changed, or how alcohol intake was associated with oestrogen metabolism over time, which may be relevant in terms of future disease risk. Alcohol was evaluated using a self-reported questionnaire and thus misreporting could lead to alcohol usage misclassification. However, misreporting of intake is not likely to be associated with endogenous hormone concentrations, so associations would likely be attenuated. The analysis was cross-sectional so we were unable to make inference about causality. We evaluated usual (12-month) frequency of alcohol consumption, but were unable to compare acute *versus* chronic alcohol exposure, or alcohol exposure across the life course. We evaluated average weekly alcohol consumption, which may not be the relevant exposure to evaluate effects on oestrogen metabolism since the timing of last alcohol ingestion could influence oestrogen concentration due to the short half-life of oestrogens ([@bib14]). Women enrolled in the WHI-OS included a subset that declined participation in WHI trials, which could have introduced selection bias in terms of alcohol exposure, although participants of the WHI clinical trials ([@bib21]; [@bib37]; [@bib46]) had a similar distribution of alcohol consumption to the observational study ([@bib28]). Future studies would also benefit from evaluating adrenal steroid precursors to oestrogens in addition to the analytes evaluated in the current study. We did not have participant genotype data; evaluating gene--alcohol interaction in relation to oestrogen hormone metabolism could contribute to the literature in this area.

In conclusion, this study strengthens the evidence that alcohol consumption increases circulating oestrogen among postmenopausal women. Our observations suggest that alcohol, specifically liquor, influences parent oestrogen concentrations, potentially through increased oestrogen production, as opposed to modifying oestrogen metabolism. Future large, prospective studies with larger average dose of alcohol consumption are needed to further explore alcohol's differential effects on oestrogen metabolism in the 2-, 4-, and 16-hydroxylation pathways.
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###### Characteristics of study participants in the Women's Health Initiative (WHI) Observational Study (OS) by alcohol category, stratified by menopausal hormone therapy (MHT) use

                                                     **Never/former MHT users (*****N*****=983)**[a](#t1-fn2){ref-type="fn"}   **Current MHT users (*****N*****=881)**                                                                                                                    
  -------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------- -------- ----- ------ -------- ----- ------- -------- ----- ------- -------- ----- ------ -------- ----- ------- --------
  **Age at blood draw (years)**                                                                                                                                                                                                                                                           
  \<60                                               259                                                                       8029                                       \(26\)  106   3000    \(10\)  153   5029     \(16\)  297   10792    \(43\)  84    3471    \(14\)  213    7321    \(29\)
  60--69                                             433                                                                       13635                                      \(44\)  170   5079    \(16\)  263   8556     \(28\)  397   10689    \(42\)  129   3765    \(15\)  268    6924    \(27\)
  70--79                                             961                                                                       31002                                      \(30\)  114   3802    \(12\)  155   5536     \(18\)  187   3840     \(15\)  65    1607    \(6\)   122    2233    \(9\)
  **Year of blood draw**                                                                                                                                                                                                                                                                  
  1993--1996                                         588                                                                       18988                                      \(61\)  236   7148    \(23\)  352   11841    \(38\)  546   15655    \(62\)  164   5473    \(22\)  382    10182   \(40\)
  1997--1998                                         373                                                                       12014                                      \(39\)  154   4733    \(15\)  219   7280     \(23\)  335   9666     \(38\)  114   3370    \(13\)  221    6296    \(25\)
  **Race**                                                                                                                                                                                                                                                                                
  White                                              844                                                                       27738                                      \(89\)  310   9684    \(31\)  534   18054    \(58\)  827   23616    \(93\)  244   7736    \(31\)  583    15880   \(63\)
  Non-white                                          117                                                                       3264                                       \(11\)  80    2197    \(7\)   37    1067     \(3\)   54    1705     \(7\)   34    1108    \(4\)   20     597.5   \(2\)
  **Smoking status**                                                                                                                                                                                                                                                                      
  Never                                              489                                                                       15517                                      \(51\)  232   7215    \(24\)  257   8302     \(27\)  429   11624    \(46\)  162   5104    \(20\)  267    6520    \(26\)
  Former                                             397                                                                       12531                                      \(41\)  128   3497    \(11\)  269   9034     \(29\)  412   12271    \(49\)  103   3153    \(12\)  309    9118    \(36\)
  Current                                            67                                                                        2630                                       \(9\)   25    1048    \(3\)   42    1582     \(5\)   35    1348     \(5\)   10    510     \(2\)   25      838    \(3\)
  **Body mass index (kg m**^**−2**^)                                                                                                                                                                                                                                                      
  \<25                                               349                                                                       13671                                      \(44\)  112   4214    \(14\)  237   9457     \(31\)  447   11554    \(46\)  116   3317    \(13\)  331    8236    \(33\)
  25--\<30                                           295                                                                       9352                                       \(30\)  125   4180    \(14\)  170   5172     \(17\)  258   7903     \(31\)  85    2788    \(11\)  173    5115    \(20\)
  30+                                                315                                                                       7894                                       \(26\)  151   3401    \(11\)  164   4493     \(15\)  175   5810     \(23\)  77    2738    \(11\)  98     3071    \(12\)
  **Years since menopause**                                                                                                                                                                                                                                                               
  \<10                                               299                                                                       9267                                       \(31\)  105   3144    \(11\)  194   6123     \(21\)  351   11154    \(44\)  95    3204    \(13\)  256    7950    \(31\)
  10--\<20                                           361                                                                       11390                                      \(39\)  146   3953    \(13\)  215   7437     \(25\)  331   8838     \(35\)  111   3472    \(14\)  220    5367    \(21\)
  20+                                                252                                                                       8888                                       \(30\)  114   3924    \(13\)  138   4964     \(17\)  199   5328     \(21\)  72    2167    \(9\)   127    3161    \(12\)
  **Duration of oral contraceptive use (years)**                                                                                                                                                                                                                                          
  Never                                              618                                                                       18930                                      \(61\)  255   7722    \(25\)  363   11208    \(36\)  453   11445    \(45\)  155   4158    \(16\)  298    7287    \(29\)
  \<5                                                182                                                                       6476                                       \(21\)  79    2367    \(8\)   103   4109     \(13\)  212   6085     \(24\)  59    1833    \(7\)   153    4252    \(17\)
  5+                                                 160                                                                       5518                                       \(18\)  55    1715    \(6\)   105   3804     \(12\)  216   7791     \(31\)  64    2853    \(11\)  152    4938    \(20\)
  **Caffeine intake quartile (median mg per day)**                                                                                                                                                                                                                                        
  1                                                  235                                                                       7360                                       \(24\)  122   3638    \(12\)  113   3722     \(12\)  222   6354     \(25\)  96    3318    \(13\)  126    3036    \(12\)
  2                                                  232                                                                       7598                                       \(25\)  91    2798    \(9\)   141   4800     \(15\)  229   5850     \(23\)  69    2061    \(8\)   160    3789    \(15\)
  3                                                  224                                                                       7613                                       \(25\)  79    2838    \(9\)   145   4775     \(15\)  238   6992     \(28\)  48    1475    \(6\)   190    5517    \(22\)
  4                                                  270                                                                       8431                                       \(27\)  98    2607    \(8\)   172   5824     \(19\)  191   6069     \(24\)  65    1990    \(8\)   126    4079    \(16\)
  **Sedentary/sitting time (hours per day)**                                                                                                                                                                                                                                              
  \<5                                                332                                                                       11519                                      \(37\)  122   4258    \(14\)  210   7261     \(24\)  306   8285     \(33\)  98    3117    \(12\)  208    5169    \(21\)
  5 to 9                                             398                                                                       12407                                      \(40\)  164   4664    \(15\)  234   7743     \(25\)  351   9994     \(40\)  107   3020    \(12\)  244    6974    \(28\)
  10+                                                224                                                                       6809                                       \(22\)  102   2957    \(10\)  122   3853     \(13\)  220   6798     \(27\)  72    2662    \(11\)  148    4136    \(16\)
  **MET hours per week**                                                                                                                                                                                                                                                                  
  None                                               206                                                                       6139                                       \(20\)  99    2814    \(9\)   107   3325     \(11\)  145   4642     \(18\)  67    2188    \(9\)   78     2454    \(10\)
  \>0--\<7.5                                         216                                                                       6724                                       \(22\)  96    2724    \(9\)   120   4000     \(13\)  216   7180     \(28\)  69    2319    \(9\)   147    4861    \(19\)
  7.5--15                                            224                                                                       7586                                       \(25\)  89    3111    \(10\)  135   4475     \(15\)  196   4671     \(18\)  73    2174    \(9\)   123    2497    \(10\)
  ⩾15                                                303                                                                       10407                                      \(34\)  101   3171    \(10\)  202   7236     \(23\)  319   8771     \(35\)  68    2109    \(8\)   251    6661    \(26\)

Abbreviations: kg=kilograms; MET=metabolic equivalent; MHT=menopausal hormone therapy; Wt=weighted.

Frequencies for never drinkers and past drinkers were similar.

Percentages reflect weighted counts and refer to the study cohort.

###### Geometric means (pmol l^−1^) and 95% confidence intervals (CI) of serum oestrogens and oestrogen metabolites by total alcohol consumption category among postmenopausal women not using menopausal hormone therapy in the Women\'s Health Initiative (WHI) Observational Study (OS)

  **Alcoholic drinks per week**                                **Non-drinker**                             **Current drinker**                                                                            **\<1**                          **1 to \<3**                   **3 to \<7**              **7+**                
  ----------------------------------------- ----------------------------------------------------- ------------------------------------- ----------------------------------------------------- ------------------------------- -------------------------------------- ---------------------- ---------------------- ----- ------
  Median                                                              0                                            2.6                                                                                      0.4                                1.8                             4                     11.5                 
  *N*                                                                398                                           565                                                                                      198                                138                            101                    148                  
  Weighted *N*[a](#t2-fn1){ref-type="fn"}                          11 881                                        19 121                                                                                    6560                                4195                           3322                   5044                 
                                             Geometric means (95% CI)[b](#t2-fn2){ref-type="fn"}   *P*-diff[c](#t2-fn3){ref-type="fn"}  Geometric means (95% CI)[b](#t2-fn2){ref-type="fn"}    %Δ[d](#t2-fn4){ref-type="fn"}   *p*-trend[e](#t2-fn5){ref-type="fn"}                                                      
  Oestrone                                                  313.8 (266.1, 370.0)                          332.6 (278.3, 397.6)          0.50                                                       314.3 (255.2, 387.1)                290.7 (223.2, 378.6)           403.3 (301.2, 540.0)   340.4 (268.7, 431.3)  8%    0.66
  Conjugated                                                245.2 (204.4, 294.1)                          266.8 (218.9, 325.3)          0.37                                                       249.2 (197.6, 314.3)                229.8 (171.1, 308.6)           320.5 (231.6, 443.7)   279.3 (216.0, 361.1)  12%   0.50
  Unconjugated                                                60.6 (53.7, 68.5)                             58.9 (51.8, 66.9)           0.66                                                         58.9 (50.5, 68.6)                  52.9 (44.3, 63.1)              73.9 (60.0, 90.9)      55.5 (46.6, 66.3)    −6%   0.51
  Oestradiol                                                  60.0 (50.3, 71.6)                             57.7 (47.6, 70.0)           0.67                                                         53.8 (43.1, 67.3)                  53.6 (42.4, 67.9)              72.0 (52.2, 99.3)      57.3 (44.6, 73.7)    6%    0.82
  Conjugated                                                  38.6 (32.0, 46.7)                             39.7 (32.1, 49.1)           0.77                                                         36.5 (28.4, 46.9)                  39.5 (30.5, 51.1)              47.6 (33.9, 66.8)      39.3 (29.7, 52.2)    8%    0.88
  Unconjugated                                                15.9 (13.1, 19.3)                             13.5 (11.2, 16.1)           0.09                                                         13.2 (10.6, 16.4)                   10.7 (8.4, 13.7)              17.6 (12.8, 24.3)      13.4 (10.8, 16.7)    2%    0.67
  2-Hydroxyoestrone                                           68.7 (59.4, 79.5)                             68.1 (58.2, 79.8)           0.91                                                         65.8 (54.6, 79.2)                   59 (47.3, 73.7)               80.4 (61.2, 105.6)     69.6 (57.7, 84.1)    6%    0.52
  2-Hydroxyoestradiol                                         16.9 (14.6, 19.5)                             16.9 (14.6, 19.7)           0.97                                                         16.5 (13.8, 19.9)                  14.6 (11.7, 18.1)              19.7 (15.2, 25.5)      17.3 (14.4, 20.9)    5%    0.52
  2-Methoxyoestrone                                           43.5 (38.6, 48.9)                             43.3 (38.2, 49.1)           0.95                                                         42.1 (35.9, 49.4)                  38.2 (31.9, 45.8)              49.0 (39.2, 61.3)      44.4 (37.6, 52.6)    6%    0.38
  Conjugated                                                  31.9 (28.0, 36.3)                             31.9 (27.9, 36.5)           0.98                                                         30.8 (25.8, 36.8)                  27.8 (22.9, 33.7)              35.0 (27.6, 44.5)      33.7 (28.2, 40.2)    9%    0.23
  Unconjugated                                                10.3 (9.0, 11.9)                              10.0 (8.6, 11.6)            0.65                                                          9.9 (8.2, 12.1)                    9.4 (7.5, 11.7)                12.1 (9.3, 15.7)       9.5 (7.7, 11.6)     −5%   0.63
  2-Methoxyoestradiol                                         13.9 (12.0, 16.2)                             14.1 (11.9, 16.8)           0.81                                                         13.8 (11.5, 16.6)                   12.1 (9.7, 15.2)               17 (12.7, 22.8)       14.3 (11.5, 17.7)    4%    0.56
  Conjugated                                                  11.2 (9.5, 13.3)                              11.5 (9.5, 13.8)            0.75                                                         11.1 (9.1, 13.6)                    9.3 (7.2, 12.2)               14.0 (10.3, 19.2)       11.9 (9.5, 14.9)    7%    0.32
  Unconjugated                                                 2.2 (1.9, 2.5)                                2.1 (1.8, 2.4)             0.56                                                          2.1 (1.7, 2.5)                      2.0 (1.7, 2.5)                 2.3 (1.8, 3.0)         2.0 (1.7, 2.4)     −2%   0.48
  3-Methyl ether-hydroxyoestrone                               7.7 (6.8, 8.7)                                 7.8 (6.8, 9)              0.76                                                          7.7 (6.5, 9.0)                      7.0 (5.8, 8.4)                8.2 (6.4, 10.4)         8.2 (6.9, 9.8)     7%    0.51
  4-Hydroxyoestrone                                            8.4 (7.3, 9.7)                                8.5 (7.3, 10.0)            0.85                                                          8.3 (6.9, 10.0)                     7.4 (5.9, 9.2)                9.9 (7.5, 13.1)        8.6 (7.1, 10.4)     4%    0.61
  4-Methoxyoestrone                                            4.6 (4.1, 5.2)                                4.5 (3.9, 5.1)             0.71                                                          4.6 (3.9, 5.4)                      3.9 (3.2, 4.6)                 4.9 (3.8, 6.2)         4.6 (3.9, 5.4)     −1%   0.57
  4-Methoxyoestradiol                                          2.0 (1.7, 2.3)                                2.0 (1.7, 2.4)             0.65                                                          2.0 (1.7, 2.5)                      1.8 (1.5, 2.3)                 2.4 (1.8, 3.2)         2.0 (1.6, 2.4)     −2%   0.95
  16-Alphahydroxyoestrone                                     34.3 (29.5, 40.0)                             34.0 (28.7, 40.2)           0.90                                                         32.6 (26.8, 39.6)                  29.5 (23.3, 37.4)              40.2 (29.7, 54.4)      34.9 (28.7, 42.5)    7%    0.51
  Oestriol                                                  147.1 (127.1, 170.2)                          144.5 (122.5, 170.5)          0.82                                                       142.0 (116.6, 172.9)                126.7 (99.4, 161.6)            171.0 (127.2, 229.9)   144.3 (118.5, 175.7)  2%    0.88
  Conjugated                                                 115.6 (97.8, 136.7)                            114.3 (95, 137.6)           0.90                                                        111.9 (89.5, 139.8)                101.4 (77.6, 132.6)            137.3 (99.8, 188.9)    113.1 (90.4, 141.5)   1%    0.99
  Unconjugated                                                27.8 (24.7, 31.3)                             26.0 (22.8, 29.8)           0.38                                                         25.7 (21.8, 30.3)                   21.8 (17.6, 27)               29.5 (22.7, 38.4)       27.1 (23, 31.8)     5%    0.25
  16-Ketooestradiol                                           36.9 (31.6, 43.1)                             37.3 (31.5, 44.3)           0.88                                                         36.3 (29.7, 44.5)                  32.2 (25.1, 41.3)              43.0 (31.7, 58.5)      38.4 (31.3, 47.1)    6%    0.64
  16-Epioestriol                                              15.8 (13.7, 18.1)                             15.5 (13.3, 18.1)           0.80                                                         14.2 (11.9, 17.1)                  13.8 (11.1, 17.1)              18.5 (14.3, 24.1)      16.2 (13.5, 19.5)    14%   0.26
  17-Epioestriol                                              12.4 (10.9, 14.2)                              12.7 (11, 14.6)            0.76                                                         11.9 (10.0, 14.2)                   11.1 (9.1, 13.6)              14.6 (11.6, 18.4)      13.4 (11.1, 16.1)    12%   0.28

Weighted *N*: frequency counts weighted to whole WHI-OS cohort.

Adjusted for age at blood draw (\<60, 60--\<70, ⩾70 years), year of blood draw (1993--1996, 1997--1998), race (white, non-white), smoking status (never smoked, past smoker, current smoker), BMI (kg m^−2^), years since menopause (\<10 years, 10--\<20 years, ⩾20 years), duration of oral contraceptive use (0, \<5, ⩾5 years), caffeine intake (quartiles), sedentary/sitting time (\<5, 5--\<10, ⩾10 h per day), and metabolic equivalent (MET) hours of physical activity per week (none, \>0--\<7.5, 7.5--15 (National recommendations), ⩾15).

*P*-diff refers to the *P*-value comparing the geometric mean concentration of parent oestrogens and oestrogen metabolites for current compared with non-alcohol drinkers. Calculated using the Wald test.

%Δ is the percentage difference in oestrogen concentrations comparing 7+ and \<1 standard alcoholic drink/week.

*P*-trend is the *P*-value for trend in association between alcohol consumption and parent oestrogens and oestrogen metabolite concentration among current drinkers. Calculated using Wald test for a continuous drinking variable based on the median number of standard servings of alcohol consumed per week according to the categories presented in the table.

###### Geometric means (pmol l^−1^) and 95% confidence intervals (CI) of serum oestrogens and oestrogen metabolites by total alcohol consumption category among postmenopausal women currently using menopausal hormone therapy in the Women\'s Health Initiative (WHI) Observational Study (OS)

  **Alcoholic drinks per week**                                **Nondrinker**                              **Current drinker**                                                                            **\<1**                          **1 to \<3**                    **3 to \<7**                 **7+**                  
  ----------------------------------------- ----------------------------------------------------- ------------------------------------- ----------------------------------------------------- ------------------------------- -------------------------------------- ------------------------- ------------------------- ----- ---------------------------------
  Median                                                              0                                            2.7                                                                                      0.4                                1.9                              4.5                      10.5                   
  *N*                                                                278                                           603                                                                                      199                                136                              125                       142                   
  Weighted *N*[a](#t3-fn1){ref-type="fn"}                           8843                                         16 478                                                                                    5310                                3639                            3694                      3779                   
                                             Geometric means (95% CI)[b](#t3-fn2){ref-type="fn"}   *P*-diff[c](#t3-fn3){ref-type="fn"}  Geometric means (95% CI)[b](#t3-fn2){ref-type="fn"}    %Δ[d](#t3-fn4){ref-type="fn"}   *p*-trend[e](#t3-fn5){ref-type="fn"}                                                            
  Oestrone                                                 2835.3 (2147.4, 3743.5)                       3468.8 (2606.5, 4616.4)        0.10                                                      3411.3 (2476.0, 4700.0)            3171.6 (2051.0, 4904.4)          3386.1 (2320.6, 4940.9)   4013.1 (2808.6, 5734.1)  18%   0.10
  Conjugated                                               2601.9 (1955.2, 3462.6)                       3167.2 (2361.9, 4247.1)        0.12                                                      3196.5 (2301.7, 4439.3)            2806.4 (1785.0, 4412.4)          3091.4 (2094.2, 4563.5)   3614.9 (2499.4, 5228.2)  13%   0.15
  Unconjugated                                              205.5 (167.9, 251.5)                          221.3 (178.6, 274.2)          0.45                                                       218.8 (171.0, 280.0)                174.4 (127.0, 239.6)            231.6 (170.2, 315.3)      276.2 (209.9, 363.3)    26%   0.01[f](#t3-fn6){ref-type="fn"}
  Oestradiol                                                403.7 (306.3, 532.2)                          438.5 (333.7, 576.2)          0.48                                                       393.9 (286.2, 542.3)                435.5 (289.3, 655.7)            445.8 (312.0, 637.0)      525.4 (376.5, 733.2)    33%   0.02[f](#t3-fn6){ref-type="fn"}
  Conjugated                                                342.8 (251.1, 468.1)                          360.4 (267.5, 485.4)          0.70                                                       338.1 (239.8, 476.8)                344.7 (217.4, 546.3)            350.0 (237.7, 515.4)      436.8 (302.8, 630.0)    29%   0.04[f](#t3-fn6){ref-type="fn"}
  Unconjugated                                                40.4 (32.0, 51.0)                             45.8 (36.2, 57.8)           0.21                                                         41.7 (31.3, 55.7)                  41.2 (30.1, 56.5)                52.6 (36.8, 75.1)         52.6 (38.8, 71.3)     26%   0.04[f](#t3-fn6){ref-type="fn"}
  2-Hydroxyoestrone                                         408.2 (329.3, 506.1)                          441.9 (356.4, 547.9)          0.42                                                       447.5 (345.6, 579.4)                409.0 (299.1, 559.3)            437.9 (321.8, 595.8)      472.2 (358.2, 622.4)    6%    0.25
  2-Hydroxyoestradiol                                        100.0 (82.1, 121.8)                           101.3 (82.5, 124.4)          0.89                                                        105.6 (82.4, 135.4)                 89.1 (66.2, 119.9)              99.7 (73.9, 134.7)        109.1 (83.5, 142.4)    3%    0.25
  2-Methoxyoestrone                                         250.8 (209.8, 299.9)                          248.4 (206.2, 299.1)          0.92                                                       248.6 (195.3, 316.5)                202.1 (152.8, 267.4)            270.2 (208.2, 350.6)      281.7 (218.6, 363.1)    13%   0.05
  Conjugated                                                155.4 (124.4, 194.0)                          149.3 (120.3, 185.2)          0.69                                                       157.7 (121.6, 204.6)                126.1 (92.3, 172.1)             153.3 (115.2, 204.1)      156.5 (116.7, 209.9)    −1%   0.46
  Unconjugated                                                68.9 (53.1, 89.4)                             72.0 (55.8, 92.9)           0.73                                                         67.4 (48.7, 93.3)                  54.6 (38.4, 77.5)               84.4 (58.6, 121.6)        92.4 (65.8, 129.6)     37%   0.01[f](#t3-fn6){ref-type="fn"}
  2-Methoxyoestradiol                                        81.5 (63.2, 105.2)                            80.3 (63.1, 102.2)           0.88                                                        77.6 (58.8, 102.4)                  69.5 (49.4, 97.9)               84.0 (61.6, 114.6)        94.6 (70.6, 126.8)     22%   0.02[f](#t3-fn6){ref-type="fn"}
  Conjugated                                                  70.8 (53.7, 93.3)                             66.4 (51.1, 86.1)           0.54                                                         66.8 (49.6, 90.1)                  56.0 (38.5, 81.5)                67.2 (48.2, 93.6)        77.2 (56.2, 106.1)     16%   0.06
  Unconjugated                                                 8.0 (6.6, 9.7)                                8.9 (7.5, 10.7)            0.23                                                          8.7 (6.9, 11.1)                    7.7 (5.9, 10.2)                  9.5 (7.1, 12.7)          10.2 (8.0, 13.0)      17%   0.04[f](#t3-fn6){ref-type="fn"}
  3-Methyl ether-hydroxyoestrone                              39.4 (32.1, 48.4)                             39.4 (32.1, 48.3)           0.99                                                         40.8 (32.1, 51.9)                  30.5 (23.0, 40.6)                43.5 (33.4, 56.7)         43.7 (33.7, 56.6)     7%    0.09
  4-Hydroxyoestrone                                            54.1 (43.6, 67)                              58.9 (47.3, 73.4)           0.39                                                         59.9 (46.1, 77.8)                  54.4 (39.7, 74.7)                59.2 (43.4, 80.7)         61.9 (46.8, 81.9)     3%    0.33
  4-Methoxyoestrone                                           24.9 (20.6, 30.1)                             25.7 (21.4, 30.9)           0.75                                                         25.9 (20.4, 32.9)                  21.2 (16.3, 27.7)                28.5 (22.1, 36.6)         27.7 (21.9, 35.1)     7%    0.16
  4-Methoxyoestradiol                                         10.6 (8.0, 13.9)                              10.7 (8.2, 13.9)            0.91                                                         10.6 (7.8, 14.4)                    9.0 (6.3, 13.0)                 11.1 (7.9, 15.6)          12.5 (9.2, 17.0)      18%   0.05
  16-Alphahydroxyoestrone                                   216.0 (172.0, 271.3)                          235.0 (187.9, 294.0)          0.40                                                       239.9 (183.9, 312.9)                213.8 (155.4, 293.9)            237.8 (172.8, 327.3)      247.1 (185.1, 329.7)    3%    0.30
  Oestriol                                                  983.7 (770.7, 1255.5)                         1134.9 (886.5, 1453)          0.19                                                      1105.7 (833.1, 1467.6)              1110.2 (776.9, 1586.4)          1210.8 (850.2, 1724.4)    1140.0 (830.3, 1565.1)   3%    0.47
  Conjugated                                                849.8 (659.8, 1094.5)                         975.5 (754.7, 1261.1)         0.23                                                       967.7 (719.1, 1302.3)              946.7 (654.7, 1369.0)           1049.9 (724.8, 1520.9)     949.5 (675.6, 1334.5)   −2%   0.69
  Unconjugated                                               117.9 (96.3, 144.4)                           122.3 (98.5, 151.9)          0.68                                                       129.3 (101.6, 164.6)                 95.1 (69.9, 129.3)              133.0 (98.8, 179.1)      132.0 (101.4, 171.8)    2%    0.20
  16-Ketooestradiol                                         245.2 (195.0, 308.5)                          275.3 (219.9, 344.8)          0.27                                                       277.7 (212.4, 363.0)                251.2 (180.7, 349.2)            286.1 (205.6, 398.0)      287.0 (213.4, 385.9)    3%    0.34
  16-Epioestriol                                              77.0 (62.6, 94.8)                             79.6 (64.4, 98.3)           0.74                                                        83.8 (65.2, 107.7)                  68.6 (50.5, 93.3)               84.6 (64.1, 111.7)        79.6 (60.2, 105.3)     −5%   0.56
  17-Epioestriol                                              54.2 (43.8, 67.0)                             54.8 (44.0, 68.3)           0.91                                                         56.4 (43.6, 73.0)                  48.4 (35.3, 66.5)                59.6 (44.6, 79.7)         54.4 (40.3, 73.5)     −4%   0.58

Weighted *N*: frequency counts weighted to whole WHI-OS Cohort.

Adjusted for age at blood draw (\<60, 60--\<70, ⩾70 years), year of blood draw (1993--1996, 1997--1998), race (white, non-white), smoking status (never smoked, past smoker, current smoker), BMI (kg m^−2^), years since menopause (\<10 years, 10--\<20 years, ⩾20 years), duration of oral contraceptive use (0, \<5, ⩾5 years), caffeine intake (quartiles), sedentary/sitting time (\<5, 5--\<10, ⩾10 h per day), and metabolic equivalent (MET) hours of physical activity per week (none, \>0--\<7.5, 7.5--15 (National recommendations), ⩾15).

*P*-diff refers to the *P*-value comparing the geometric mean concentration of parent oestrogens and oestrogen metabolites for current compared with non-alcohol drinkers. Calculated using the Wald test.

%Δ is the percentage difference in oestrogen concentrations comparing 7+ and \<1 standard alcoholic drink/week.

*P*-trend is the *P*-value for trend in association between alcohol consumption and parent oestrogens and oestrogen metabolite concentration among current drinkers. Calculated using Wald test for a continuous drinking variable based on the median number of standard servings of alcohol consumed per week according to the categories presented in the table.

Nominal *P*-value\<0.05.

###### Geometric means (pmol l^−1^) and 95% confidence intervals (CI) of serum oestrogens and oestrogen metabolites by liquor, beer and wine consumption category among postmenopausal alcohol drinkers who are never/former menopausal hormone therapy users in the Women\'s Health Initiative (WHI) Observational Study (OS)

                                                                     Liquor                                          Beer                                     Wine                                                                                                                                                                                                                                                                                                                                                                                                                       
  ----------------------------------------- --------------------------------------------------------- ----------------------------------- --------------------------------------------- --------------------------------------------------------- ----------------------------------- --------------------------------------------- --------------------------------------------------------- ----------------------------------- --------------------------------------------- ------ ---------------------- ---------------------- ---------------------- ---------------------- ----- ------
  Alcoholic drinks/week                                      **Non-liquor drinker**                               **\>0--1**                                   \>1                                                                                                                                **Non-beer drinker**                                     **\>0--1**                                       **\>1**                                                                     **Non-wine drinker**        **\>0--1**             **\>1--3**              **\>3**                
  Median                                                                0                                            0.42                                     5.25                                                                                                                                          0                                                 0.422                                          2.73                                                                                0                     0.42                   2.73                    7                   
  *N*                                                                  299                                            166                                      120                                                                                                                                         391                                                 137                                            57                                                                                 91                    262                    113                    119                  
  Weighted *N*[a](#t4-fn1){ref-type="fn"}                             9977                                           5277                                     3867                                                                                                                                        13114                                               3910                                           2097                                                                               2638                   8938                   3205                   4341                 
                                             **Geometric means (95% CI)**[b](#t4-fn2){ref-type="fn"}   **%Δ**[c](#t4-fn3){ref-type="fn"}   ***p*****-diff**[d](#t4-fn4){ref-type="fn"}  **Geometric means (95% CI)**[b](#t4-fn2){ref-type="fn"}   **%Δ**[c](#t4-fn3){ref-type="fn"}    ***p*****-diff**[d](#t4-fn4){ref-type="fn"}   **Geometric means (95% CI)**[b](#t4-fn2){ref-type="fn"}   **%Δ**[c](#t4-fn3){ref-type="fn"}  ***p*****-diff**[d](#t4-fn4){ref-type="fn"}                                                                                                            
  Oestrone                                                    293.1 (242.4, 354.3)                            343.9 (266.9, 443)                      411.3 (321.3, 526.5)              29%                                                       0.007[e](#t4-fn5){ref-type="fn"}                334.0 (279.4, 399.3)                                329.9 (241.8, 450.3)                           331.0 (243.0, 451.0)         −1%                                           0.96    332.0 (252.1, 437.2)   316.8 (254.6, 394.4)   350.5 (257.6, 476.9)   355.1 (274.6, 459.0)  7%    0.68
    Conjugated                                                230.5 (186.4, 285.1)                           278.2 (211.1, 366.7)                     340.2 (260.1, 444.9)              32%                                                       0.004[e](#t4-fn5){ref-type="fn"}                270.2 (221.7, 329.4)                                258.5 (183.1, 365.1)                           265.6 (188.8, 373.6)         −2%                                           0.92    273.7 (202.5, 369.9)   249.6 (195.8, 318.2)   277.7 (197.9, 389.8)   292.6 (221.8, 386.0)  7%    0.70
    Unconjugated                                                55.4 (48.4, 63.4)                              59.2 (48.7, 72.0)                        65.8 (54.4, 79.5)               16%                                                       0.07                                              58.2 (51.0, 66.6)                                   61.7 (49.8, 76.4)                              57.8 (46.7, 71.5)          −1%                                           0.94     54.5 (44.4, 66.9)      59.6 (51.2, 69.4)      63.9 (51.9, 78.7)      57.1 (47.0, 69.5)    5%    0.71
  Oestradiol                                                    53.3 (43.3, 65.6)                              61.8 (47.1, 81.1)                        63.4 (48.7, 82.6)               16%                                                       0.19                                               57 (47.4, 68.6)                                    62.3 (44.8, 86.6)                              55.3 (40.5, 75.6)          −3%                                           0.85     56.1 (42.5, 74.1)      54.4 (43.6, 67.8)      63.9 (46.0, 88.8)      62.2 (48.0, 80.6)    11%   0.52
    Conjugated                                                  37.1 (29.6, 46.6)                              44.5 (33.1, 59.7)                        40.9 (30.6, 54.7)               9%                                                        0.50                                              38.5 (31.4, 47.3)                                   44.3 (30.8, 63.7)                              38.7 (27.2, 55.0)          0%                                            0.98     39.7 (29.5, 53.6)      36.8 (29.1, 46.7)      44.3 (30.6, 64.3)      42.5 (31.7, 57.2)    7%    0.70
    Unconjugated                                                12.0 (9.8, 14.7)                               13.3 (10.4, 16.9)                        17.0 (12.9, 22.5)               30%                                                       0.014[e](#t4-fn5){ref-type="fn"}                  13.8 (11.4, 16.9)                                   13.2 (10.1, 17.1)                              12.6 (9.6, 16.6)           −10%                                          0.50      13.1 (9.8, 17.4)      13.2 (10.6, 16.6)      13.5 (10.3, 17.7)      14.4 (11.4, 18.2)    10%   0.54
  2-Hydroxyoestrone                                             62.5 (52.8, 73.9)                              66.7 (53.0, 84.0)                       82.0 (67.1, 100.2)               24%                                                       0.009[e](#t4-fn5){ref-type="fn"}                  68.5 (58.2, 80.7)                                   69.6 (53.6, 90.3)                              65.5 (50.7, 84.8)          −4%                                           0.75     68.0 (53.4, 86.6)      66.2 (55.3, 79.3)      69.9 (53.4, 91.5)      71.3 (56.3, 90.4)    5%    0.76
  2-Hydroxyoestradiol                                           15.6 (13.2, 18.4)                              16.7 (13.4, 20.8)                        20.1 (16.5, 24.5)               22%                                                       0.016[e](#t4-fn5){ref-type="fn"}                  17.1 (14.6, 20.0)                                   17.4 (13.5, 22.4)                              16.1 (12.6, 20.5)          −6%                                           0.65     16.8 (13.2, 21.5)      16.6 (13.9, 19.8)      17.2 (13.3, 22.2)      17.7 (14.0, 22.5)    5%    0.74
  2-Methoxyoestrone                                             39.7 (34.6, 45.5)                              43.9 (36.1, 53.2)                        50.6 (42.2, 60.6)               22%                                                       0.012[e](#t4-fn5){ref-type="fn"}                  44.3 (39.0, 50.4)                                   43.7 (34.4, 55.5)                              39.8 (32.2, 49.2)          −11%                                          0.36     40.1 (32.9, 48.9)      42.9 (36.7, 50.0)      46.3 (36.3, 59.2)      44.9 (37.3, 54.1)    12%   0.37
    Conjugated                                                  29.4 (25.3, 34.3)                              32.3 (26.3, 39.6)                        36.9 (30.5, 44.8)               20%                                                       0.029[e](#t4-fn5){ref-type="fn"}                  33.1 (28.9, 38.1)                                   31.5 (24.2, 40.9)                              28.8 (23.0, 36.0)          −15%                                          0.26     29.0 (23.6, 35.8)      31.5 (26.8, 37.2)      33.9 (26.1, 44.0)      34.1 (28.1, 41.4)    18%   0.21
    Unconjugated                                                 9.0 (7.7, 10.6)                               10.6 (8.4, 13.2)                         11.5 (9.2, 14.5)                22%                                                       0.039[e](#t4-fn5){ref-type="fn"}                   9.7 (8.3, 11.4)                                    10.9 (8.6, 13.8)                                9.9 (7.5, 13.0)           1%                                            0.94      9.9 (7.6, 12.8)        9.9 (8.2, 12.0)        10.8 (8.3, 14.1)       9.6 (7.7, 12.1)     −2%   0.88
  2-Methoxyoestradiol                                           13.6 (11.4, 16.2)                              13.4 (10.5, 17.1)                        16.1 (12.8, 20.3)               16%                                                       0.13                                              14.7 (12.6, 17.2)                                   13.6 (10.2, 18.0)                              13.1 (9.7, 17.8)           −12%                                          0.43      12.1 (9.6, 15.3)      13.6 (11.4, 16.3)      17.1 (12.2, 23.8)      15.0 (12.2, 18.6)    24%   0.12
    Conjugated                                                  11.0 (9.0, 13.4)                               10.9 (8.4, 14.1)                         13.1 (10.3, 16.8)               16%                                                       0.15                                              11.9 (10.0, 14.2)                                   11.0 (8.1, 15.0)                               10.7 (7.7, 14.8)           −11%                                          0.49      9.9 (7.8, 12.7)        11.0 (9.0, 13.3)       13.5 (9.3, 19.8)       12.7 (10.1, 16)     28%   0.09
    Unconjugated                                                 1.9 (1.6, 2.2)                                 2.2 (1.8, 2.7)                           2.5 (2.1, 3.0)                 24%                                                       0.01[e](#t4-fn5){ref-type="fn"}                    2.2 (1.9, 2.5)                                      2.0 (1.6, 2.5)                                 2.0 (1.6, 2.5)            −8%                                           0.50       1.9 (1.5, 2.4)         2.1 (1.8, 2.5)         2.5 (1.9, 3.1)         1.9 (1.6, 2.3)     −1%   0.93
  3-Methyl ether-hydroxyoestrone                                 7.2 (6.2, 8.3)                                 7.6 (6.3, 9.2)                           9.5 (7.8, 11.4)                24%                                                       0.004[e](#t4-fn5){ref-type="fn"}                   7.8 (6.8, 9.0)                                      8.0 (6.4, 9.9)                                 7.7 (6.1, 9.5)            −2%                                           0.85       7.9 (6.6, 9.5)         7.9 (6.8, 9.3)        7.8 (6.1, 10.0)         7.5 (6.2, 9.1)     −5%   0.65
  4-Hydroxyoestrone                                              7.8 (6.6, 9.3)                                 8.1 (6.4, 10.3)                         10.4 (8.5, 12.7)                25%                                                       0.008[e](#t4-fn5){ref-type="fn"}                   8.6 (7.3, 10.2)                                     8.5 (6.6, 11.1)                                 8 (6.2, 10.4)            −8%                                           0.59      8.4 (6.5, 10.8)        8.3 (7.0, 10.0)        8.8 (6.7, 11.6)        8.7 (6.8, 11.1)     4%    0.82
  4-Methoxyoestrone                                              4.2 (3.7, 4.9)                                 4.3 (3.5, 5.3)                           5.2 (4.4, 6.2)                 19%                                                       0.026[e](#t4-fn5){ref-type="fn"}                   4.7 (4.1, 5.4)                                      4.3 (3.4, 5.5)                                 4.1 (3.3, 5.1)            −15%                                          0.21       4.2 (3.5, 5.1)         4.5 (3.9, 5.2)         4.7 (3.6, 6.1)         4.6 (3.8, 5.7)     9%    0.50
  4-Methoxyoestradiol                                             2 (1.6, 2.4)                                   2 (1.6, 2.6)                            2.1 (1.7, 2.7)                 8%                                                        0.43                                               2.1 (1.8, 2.5)                                      1.9 (1.4, 2.5)                                 1.9 (1.4, 2.5)            −12%                                          0.39       1.8 (1.4, 2.3)         2.0 (1.7, 2.4)         2.5 (1.8, 3.5)         2.0 (1.7, 2.5)     15%   0.32
  16-Alpha-hydroxyoestrone                                      31.1 (26.0, 37.1)                              33.1 (25.9, 42.4)                        41.3 (33.5, 50.9)               25%                                                       0.009[e](#t4-fn5){ref-type="fn"}                  34.3 (28.9, 40.8)                                   34.5 (26.2, 45.7)                              32.4 (24.7, 42.6)          −6%                                           0.70     33.4 (26.0, 42.9)      33.0 (27.3, 39.9)       34.9 (26, 46.9)        36.0 (28, 46.3)     8%    0.64
  Oestriol                                                    132.3 (110.4, 158.6)                           140.8 (110.8, 178.9)                     175.0 (141.7, 216.2)              24%                                                       0.013[e](#t4-fn5){ref-type="fn"}                146.2 (123.0, 173.8)                                144.9 (110.6, 189.8)                           138.9 (104.2, 185.2)         −5%                                           0.74    141.9 (111.5, 180.5)   143.3 (118.4, 173.5)   150.4 (112.6, 201.0)   144.6 (113.4, 184.4)  2%    0.90
    Conjugated                                                 103.0 (84.0, 126.4)                            114.0 (87.9, 147.9)                     140.0 (110.6, 176.7)              26%                                                       0.014[e](#t4-fn5){ref-type="fn"}                 115.9 (95.4, 140.8)                                 116.0 (86.3, 156.1)                            107.8 (77.7, 149.6)         −8%                                           0.68    112.4 (86.0, 146.9)    113.4 (91.5, 140.6)    119.0 (87.3, 162.3)    114.1 (86.9, 149.8)   2%    0.93
    Unconjugated                                                25.0 (21.5, 29.1)                              22.8 (18.5, 28.2)                        31.6 (26.2, 38.1)               21%                                                       0.029[e](#t4-fn5){ref-type="fn"}                  26.3 (22.8, 30.4)                                   25.5 (20.6, 31.7)                              25.7 (20.5, 32.2)          −2%                                           0.86     25.7 (20.8, 31.8)      25.5 (21.7, 29.8)      27.2 (20.7, 35.8)      26.7 (22.0, 32.4)    4%    0.78
  16-Ketooestradiol                                              34.1 (28.4, 41)                               35.6 (27.7, 45.8)                        46.4 (37.3, 57.7)               26%                                                       0.009[e](#t4-fn5){ref-type="fn"}                   37.7 (31.6, 45)                                    38.1 (28.7, 50.6)                              35.5 (26.6, 47.5)          −6%                                           0.71     37.5 (28.8, 48.9)      36.5 (30.0, 44.4)      38.3 (28.3, 51.9)      38.4 (29.9, 49.3)    2%    0.89
  16-Epioestriol                                                13.7 (11.6, 16.1)                              16.2 (13.0, 20.2)                        18.9 (15.6, 23.0)               28%                                                       0.001[e](#t4-fn5){ref-type="fn"}                  15.3 (13.0, 17.9)                                   16.1 (12.7, 20.4)                              15.5 (11.9, 20.2)          2%                                            0.89     16.5 (12.9, 21.2)      14.6 (12.2, 17.5)      15.3 (11.9, 19.7)      16.8 (13.5, 20.9)    2%    0.91
  17-Epioestriol                                                11.5 (9.9, 13.4)                               12.5 (10.3, 15.3)                        15.4 (12.8, 18.7)               25%                                                       0.003[e](#t4-fn5){ref-type="fn"}                  12.5 (10.8, 14.6)                                   13.0 (10.4, 16.3)                              12.8 (10.1, 16.3)          2%                                            0.87     12.9 (10.4, 15.9)      12.3 (10.3, 14.6)       12.4 (9.9, 15.7)       13.7 (11.1, 17)     7%    0.64

Weighted *N* reflects frequency counts weighted to the whole WHI-OS Cohort.

Adjusted for age at blood draw (\<60, 60--\<70, ⩾70 years), year of blood draw (1993--1996, 1997--1998), race (white, non-white), smoking status (never smoked, past smoker, current smoker), BMI (kg m^−2^), years since menopause (\<10 years, 10--\<20 years, ⩾20 years), duration of oral contraceptive use (0, \<5, ⩾5 years), caffeine intake (quartiles), sedentary/sitting time (\<5, 5--\<10, ⩾10 h per day), and metabolic equivalent (MET) hours of physical activity per week (none, \>0--\<7.5, 7.5--15 (National recommendations), ⩾15).

%Δ is the percentage difference in oestrogen concentrations comparing highest with non-alcohol type (liquor/beer/wine) drinkers.

*P*-diff refers to the *P*-value comparing the geometric mean concentration of parent oestrogens and oestrogen metabolites for highest category compared with non-alcohol type (liquor/beer/wine) drinkers. Calculated using the Wald test.

FDR q-value\<0.05.
